Jump to content
PC Security Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
  • entries
    24
  • comments
    0
  • views
    109

Presently, over 240 ADC therapy candidates are being evaluated in clinical <Roots Analysis>


With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.

 

To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

 

The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:

§  Type of Payload

§  MMAE

§  DM4

§  Camptothecin

§  DM1

§  MMAF

§  Others

 

§  Type of Linker

§  VC

§  Sulfo-SPDB

§  SMCC

§  VA

§  Hydrazone

§  Others

 

§  Target Indication

§  Breast cancer

§  Lymphoma

§  Leukemia

§  Urothelial cancer

§  Lung cancer

§  Ovarian cancer

§  Others

 

§  Target Antigen

§  CD30

§  HER2

§  CD22

§  CD33

§  Others

 

§  Technology Providers

§  Seattle Genetics

§  ImmunoGen

§  StemCentRx

§  Immunomedics

§  Others

 

§  Key Geographical Regions

§  North America

§  Europe

§  Asia Pacific

 

The Antibody Drug Conjugates Market (5th Edition), 2019-2030.”  report features the following companies, which we identified to be key players in this domain:

§  Bristol Myers Squibb

§  GlaxoSmithKline

§  Incyte

§  Novartis

§  Trillium Therapeutics

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction
 

1.     Market Overview
 

5. Company and Drug Profiles
 

6. Key Therapeutic Areas
 

7. Key Opinion Leaders 
 

8. Target Competitiveness Analysis
 

9. Partnerships and Collaborations
 

10. Funding and Investment Analysis
 

11. Patent Analysis
 

12. Academic Grants
 

13. Key Commercialization Strategies

 

14. Promotional Analysis

 

15. Combination Therapies

 

16. Novel Conjugation Technology Platforms

 

17. Assessment of Non-Clinical Data, First in Human Dosing

 

18. Cost Price Analysis

 

19. Case Study: Contract Manufacturing of ADC

 

20. Case Study: Companion Diagnostics for ADC Therapeutic

 

21. Market Forecast and Opportunity Analysis

 

22. Swot Analysis
 

23. Conclusion

 

24. Executive Insights

 

25. Appendix 1: Tabulated Data

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...